BrainGate shows early promise in human trial
This article was originally published in Clinica
Executive Summary
Cyberkinetics Neurotechnology Systems has reported positive results from preliminary trial of its implantable BrainGate Neural Interface System - a device which aims to convert brain cell impulses into computer signals. The BrainGate system aspires to give paralysed patients the ability to use their thoughts to control a computer interface, so that they can maintain simple communication skills.
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.